Medical Need of Oral Anti-coagulant Reversal in Japan: Epidemiological Assessment of Head Trauma, Fracture, and Emergency Surgery Using Large Scale Claims Database (Please Note That This Study Contains no Patients Treated With Idarucizumab Although the Study Number Begins With 1321; the Study Contains Only Patients Treated With OACs, Namely Warfarin, Dabigatran, Edoxaban, Apixaban, Rivaroxaban, Edoxaban)
Phase of Trial: Phase IV
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Edoxaban (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Atrial fibrillation
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 07 Dec 2017 Status changed from recruiting to completed.
- 06 Dec 2017 Status changed from not yet recruiting to recruiting.
- 31 Oct 2017 Planned End Date changed from 14 Dec 2017 to 26 Dec 2017.